Recombinant CSF2 (Otilimab Biosimilar) antibody
Quick Overview for Recombinant CSF2 (Otilimab Biosimilar) antibody (ABIN7676054)
Target
Antibody Type
Reactivity
Host
Clonality
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-CSF2 / GM-CSF Reference Antibody (otilimab)
-
Sequence
- QVQLVESGGG LVQPGGSLRL SCAASGFTFS SYWMNWVRQA PGKGLEWVSG IENKYAGGAT YYAASVKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAR GFGTDFWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK,DIELTQPPSV SVAPGQTARI SCSGDSIGKK YAYWYQQKPG QAPVLVIYKK RPSGIPERFS GSNSGNTATL TISGTQAEDE ADYYCSAWGD KGMVFGGGTK LTVLGQPKAA PSVTLFPPSS EELQANKATL VCLISDFYPG AVTVAWKADS SPVKAGVETT TPSKQSNNKY AASSYLSLTP EQWKSHRSYS CQVTHEGSTV EKTVAPTECS
-
Characteristics
- Anti-CSF2 / GM-CSF Reference Antibody (otilimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG1
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: GM-CSF inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- CSF2 (Otilimab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
-
UniProt
- P04141
Target
-